Evidence map›Paper›PMID 39630170›Full record

ArticleJournal of molecular histology2024

Efect of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells.

Mohammadreza Gholamrezapour, Raziyeh Taghizadeh Ghavamabadi, Mohammad Mohsen Taghavi, Samereh Dehghani Soltani, Ahmad Shabanizadeh, Reza Vazirinejad, Zahra Taghipour

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular histology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammadreza GholamrezapourDepartment of Internal Medicine, School of Medicine Ali Ibn Abitaleb Educational and Treatment Hospital, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Raziyeh Taghizadeh GhavamabadiDepartment of Basic Science, School of Veterinary Medicine, University of Tehran, Tehran, Iran.
Mohammad Mohsen TaghaviDepartment of Anatomical Sciences, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Samereh Dehghani SoltaniDepartment of Anatomical Sciences, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Ahmad ShabanizadehDepartment of Anatomical Sciences, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Reza VazirinejadDepartment of Community Medicine, School of Medicine, Social Determinants of Health Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Zahra TaghipourDepartment of Anatomical Sciences, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. taghipourz@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease is a prevalent liver condition that can progress to fibrosis and cirrhosis. It also poses a risk for hepatocellular carcinoma, underscoring the importance of identifying effective treatments. N-acetylcysteine, an inhibitor of glutathione depletion, shows promise in modulating intracellular glutathione biosynthesis and combating oxidative stress, making it a potentially beneficial therapy for liver fibrosis in non-alcoholic fatty liver disease. This study assesses the impact of N-acetylcysteine on HepG2 cells which were induced into fatty liver cells was evaluated. HepG2 cells were cultured in DMEM and seeded onto six-well plates at a density of 5 × 10

Indexed as

AcetylcysteineApoptosisFatty LiverGene Expression RegulationGlutathioneHep G2 CellsHumansLipid MetabolismLipogenesisNon-alcoholic Fatty Liver DiseaseOxidative StressAcetylcysteineGlutathioneFABP5Lipid metabolismNAFLDOil redPPARA

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.